Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal Augment-101 phase 2 study Meeting Abstract
| Authors: | Aldoss, I.; Issa, G. C.; Thirman, M.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G. N.; Perl, A.; Dickens, D. S.; McMahon, C. M.; Traer, E.; Zwaan, C. M.; Grove, C.; Stone, R.; Shami, P. J.; Mantzaris, I.; Greenwood, M.; Shukla, N.; Cuglievan, B.; Gu, Y.; Bagley, R. G.; Madigan, K.; Sunkaraneni, S.; Van Nguyen, H.; McNeer, N.; Stein, E. M. |
| Abstract Title: | Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: Topline efficacy and safety results from the pivotal Augment-101 phase 2 study |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-21 |
| Language: | English |
| ACCESSION: | WOS:001131692800006 |
| DOI: | 10.1182/blood-2023-192042 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA-5 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work